News | November 01, 2024
Supriya Lifescience reports 19% revenue increase in Q2 FY25
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Strokes are affecting approximately 1.8 million people annually
Indoco is comprehensively working on the remedial action plan
Subscribe To Our Newsletter & Stay Updated
